MEXICO CITY, July 24, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB) ("Genomma" or "the Company"), today announced its results for the second quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned. Comments from our CEO, Marco Sparvieri "We had a strong quarter, with a 6.4% Net Sales increase, a 54% EPS increase to Ps. 0.63, and EBITDA margin expanding to 22.9%; a more than 180 basis-point increase due to our productivity initiatives' continued significant progress. We saw steady growth in key markets and brands, and will continue to strengthen our core brands while we focus on achieving Ps. 1,800 MM in annual cost savings by 2027." Q2 2024 Financial Summary The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos. Q2 2024 % sales Q2 2023 % sales % var Net Sales 4,651.5 100.0 % 4,370.5 100.0 % 6.4 % Like-for-like Sales(1) 5.2 %